Federal Circuit Upholds Cephalon’s Fentora Patents But Says Watson’s Generic Doesn’t Infringe

Drug Industry Daily
A U.S. appeals courts reversed a lower court’s decision that invalidated two Cephalon patents for pain drug Fentora while still upholding the district court’s finding that Watson’s generic version did not infringe on those patents.

To View This Article:


Subscribe To Drug Industry Daily